Cite
HARVARD Citation
Rinaldi, Y. et al. (2020). Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). European journal of cancer. pp. 25-34. [Online].